The case of Ozempic as a dementia buster is building a building. This week’s study shows that GLP-1 drugs are related to the low risk of dementia in patients with type 2 diabetes.
Researchers in Ireland have led the study of existing evidence. Compared to the control group (such as other types of drugs or placebo), people in GLP-1 therapy were very likely to be diagnosed with dementia, researchers said. Other scientists and pharmaceutical companies have already started testing these drugs in clinical trials to prevent dementia.
Ozempic, Wegovy, and similar drugs can help to adjust blood sugar and appetite by imitating hormonal GLP-1 (drugs are made of active ingredient segment). The drug was first approved to lower blood sugar in type 2 diabetes patients, but now it is usually used to treat obesity.
Those who do not have the wrong diabetes of diabetes have a high risk of Alzheimer’s and other forms of dementia, and the recent clinical trials have further showed that GLP-1 therapy is possible. Reduce the probability Cardiovascular disease, another risk factor of dementia. However, researchers behind the new research show that there is a “powerful evidence” that supports the use of heart protection and glucose lowered drugs to prevent people’s dementia.
The researchers analyzed the randomized placebo control test of GLP-1 drugs and data from other glucose deterioration such as SGLT2IS. The test included about 160,000 volunteers and explicitly tracked whether dementia or cognitive impairment occurred during the study period.
The team did not find the connection between the overall use of these drugs and the low risk of dementia or cognitive impairment compared to the control. But when they looked at the drug class individually, they knew that GLP-1 drugs seemed to be noticeable with the rest.
“In this meta analysis of random trials, glucose deterioration using GLP1-RAS, not SGLT2IS or Pioglita Zone, was related to the statistically significant decrease in dementia or cognitive impairment,” the researchers wrote in the paper. Post Monday at Jama Neurology.
The result is not the first to propose a potential dementia-buffer effect from GLP-1 therapy. research Post For example, in early January, Liraglutide (old GLP-1 drug) found evidence that the brain contraction rate of the Alzheimer’s brain contraction rate (GIZMODO dealt with a study that was first released last year). Another review Post Last year, GLP-1 drugs concluded that Alzheimer’s “metabolism and neurotrental benefits” could be “.
Some scientists speculate that these drugs can reduce inflammation or improve the way brain cells can communicate, but it is not exactly clear how GLP-1 can protect the brains of those with initial dementia or high risk. It still still remains how much this protection effect actually affects. However, NOVO NORDISK, the producer of Ozempic and Wegovy, which are enhanced with initial data, It was released Two large III tests that test the semaglitide for patients with early Alzheimer’s disease are expected to be completed next year. So soon, we hope that we can get a specific answer to these questions.
